04:09 AM EDT, 05/05/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study.

A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months, the company said.

The drug, jointly developed with Johnson & Johnson ( JNJ ) subsidiary Janssen Pharmaceutica, also showed a favorable safety profile, Nanobiotix ( NBTX ) said.

The company added that the results prompted investigators to recommend further evaluation in a randomized study. The US Food and Drug Administration has also cleared researchers to expand the study to include a new cohort that has already recruited and dosed its first patient, the company said.